Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 7/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitrofen SCHEMBL38981 | 0.90 | PDE7A (0.68) | PDE7AMEN1KMT2AGAAPKM | |
| Nitrofen SCHEMBL29364713 | 0.90 | PDE7A (0.68) | PDE7AMEN1KMT2AGAAPKM | |
| Nitrofen SCHEMBL1702412 | 0.90 | PDE7A (0.68) | PDE7AMEN1KMT2AGAAPKM | |
| SCHEMBL11198374 | 0.89 | PDE7A (0.76) | PDE7AMEN1KMT2AGAAPKM | |
| Nitrofen SCHEMBL28057303 | 0.89 | PDE7A (0.67) | PDE7AMEN1KMT2AGAAPKM | |
| SCHEMBL11760667 | 0.88 | PDE7A (1.00) | PDE7AMEN1KMT2AGAAPKM | |
| Nitrofen SCHEMBL10584175 | 0.88 | PDE7A (0.65) | PDE7AMEN1KMT2AGAAPKM | |
| SCHEMBL22069562 | 0.88 | PDE7A (0.74) | PDE7AMEN1KMT2AGAAPKM | |
| SCHEMBL9367473 | 0.88 | PDE7A (0.74) | PDE7AMEN1KMT2AGAAPKM | |
| SCHEMBL4029870 | 0.87 | PDE7A (0.73) | PDE7AMEN1KMT2AGAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105461582-A | A preparing method of rafoxanide | ZHEJIANG ESIGMA BIOTECHNOLOGY CO LTD | 2016-04-06 | — | — | CN | claimed |
| EP-3666769-A1 | NOVEL CASPASE INHIBITORS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2020-06-17 | — | — | EP | disclosed |
| CN-105461582-A | A preparing method of rafoxanide | ZHEJIANG ESIGMA BIOTECHNOLOGY CO LTD | 2016-04-06 | — | — | CN | disclosed |
| US-8338605-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100256139-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-10-07 | — | — | US | disclosed |
| EP-1979349-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2010-07-28 | — | — | EP | disclosed |
| US-7763731-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2010-07-27 | — | — | US | disclosed |
| EP-1979349-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007076035-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
| US-5382686-A | Process for preparing nitrodiphenyl (thio) ethers | BAYER AKTIENGESELLSCHAFT (DE) | 1995-01-17 | — | — | US | disclosed |
| EP-0304725-B1 | PROCESS FOR THE PREPARATION OF NITRO-DIPHENYL(THIO) ETHERS | BAYER AG (DE) | 1992-01-22 | — | — | EP | disclosed |
| US-5034410-A | Nitrile and oxo containing amides or thioamides | SYNTEX (U.S.A.) INC. (US) | 1991-07-23 | — | — | US | disclosed |
| EP-0304725-A1 | Process for the preparation of nitro-diphenyl(thio) ethers | BAYER AG (DE) | 1989-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | PDE7A 4223/4885MEN1 4571/4885KMT2A 3566/4885 |
| US-20100256139-A1 | Anti-Viral Compounds | HAVCR2, MAVS, EIF2AK2 | PDE7A 4223/4885MEN1 4571/4885KMT2A 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.